Learn more about the device that is revolutionizing skin cancer detection

Complete this form and a representative will contact you about making DermaSensor your new assistant for skin cancer care.

  • Provide your information above to be contacted by a DermaSensor rep.
  • This field is for validation purposes and should be left unchanged.

[xyz-ips snippet="landing-content"]

Rapid Recording

Rapid Recording

Quick, point-and-click recordings collect and analyze non-visual spectral data quickly

Optical Spectroscopy

Optical Spectroscopy

Light-emitting tip non-invasively scans the lesion, receiving and analyzing spectral data at the cellular level from below the skin's surface

Easy to Use

Easy to Use

Wireless, ergonomic design makes the device intuitive to learn and easy to use

Risk Assessment

Immediate Result

DermaSensor's proprietary algorithm provides an instant, objective result to support your clinical decision at the point of care

How It Works


Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.


Use DermaSensor to analyze those lesions of concern to receive a Higher Risk or Lower Risk result for each lesion.


Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.

Simple Design.
Effortless Application

  • Intuitive on-screen user interface guides you step-by-step through the evaluation
  • Activate a recording using either the touch-screen interface or conveniently positioned side buttons

DermaSensor is not a camera or dermatoscope. DermaSensor uses pulses of light and elastic scattering spectroscopy to assess a lesion’s cellular and sub-cellular structures.

Ready to learn more?

Safety and Efficacy Results for DERM-ASSESS II Prospective, Multi-Centre Study

Study reported no adverse events as well as no significant difference between DermaSensor's and dermatologists' sensitivity and specificity

DermaSensor's sensitivity for melanoma was 100.0%* while the study dermatologists' was 90.9%. For BCC and SCC, also known as Non-Melanoma Skin Cancer (NMSC), DermaSensor's sensitivity was 93.3% and the dermatologists' was 98.3%

DermaSensor Device and Dermatologist Sensitivity For Skin Cancers
Overall Sensitivity
Melanoma Sensitivity
NMSC Sensitivity
DermaSensor Device
Dermatologist In-Person Assessment
False-positive and false-negative results may lead to unnecessary care or to a malignant skin lesion not being optimally managed, respectively. However, it is important to note that biopsy is used to confirm pathology and that elastic scattering spectroscopy is to be used as an adjunctive tool to visual inspection and history-taking. See all Claims and Substantiations

©2020 DermaSensor, inc

Scroll to Top